Johnson & Johnson (JNJ) Earning Somewhat Critical Media Coverage, Analysis Shows
News headlines about Johnson & Johnson (NYSE:JNJ) have trended somewhat negative recently, InfoTrie reports. The research group identifies negative and positive news coverage by analyzing more than 6,000 news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Johnson & Johnson earned a daily sentiment score of -1.73 on their scale. InfoTrie also gave news coverage about the company an news buzz score of 4 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the news headlines that may have impacted Johnson & Johnson’s analysis:
- J&J Slammed by Concern Over Baby Powder Safety (wsj.com)
- Johnson & Johnson (JNJ) Updates FY18 Earnings Guidance (americanbankingnews.com)
- J&J moves to limit impact of Reuters report on asbestos in Baby Powder (feeds.reuters.com)
- UPDATE 3-J&J moves to limit impact of Reuters report on asbestos in Baby Powder (feeds.reuters.com)
- Cramer Remix: Johnson & Johnson has to stop dropping for the market to head higher (cnbc.com)
Shares of JNJ stock opened at $129.14 on Tuesday. The company has a quick ratio of 1.40, a current ratio of 1.72 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a 12-month low of $118.62 and a 12-month high of $148.99. The company has a market cap of $356.83 billion, a PE ratio of 17.69, a P/E/G ratio of 2.08 and a beta of 0.59.
The business also recently declared a quarterly dividend, which was paid on Tuesday, December 11th. Stockholders of record on Tuesday, November 27th were paid a dividend of $0.90 per share. The ex-dividend date of this dividend was Monday, November 26th. This represents a $3.60 annualized dividend and a dividend yield of 2.79%. Johnson & Johnson’s payout ratio is currently 49.32%.
Several equities analysts have commented on the stock. Credit Suisse Group set a $149.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a research report on Sunday, October 14th. Raymond James lifted their target price on shares of Johnson & Johnson from $144.00 to $149.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 17th. HC Wainwright reissued a “buy” rating on shares of Johnson & Johnson in a research report on Wednesday, October 17th. Zacks Investment Research cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Tuesday, December 4th. Finally, Citigroup lifted their target price on shares of Johnson & Johnson from $137.00 to $148.00 and gave the stock a “neutral” rating in a research report on Monday, October 22nd. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and ten have issued a buy rating to the company. Johnson & Johnson currently has an average rating of “Hold” and an average price target of $142.58.
In related news, CEO Alex Gorsky sold 264,465 shares of Johnson & Johnson stock in a transaction that occurred on Friday, November 16th. The shares were sold at an average price of $145.96, for a total value of $38,601,311.40. Following the completion of the transaction, the chief executive officer now directly owns 481,254 shares in the company, valued at approximately $70,243,833.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Charles Prince acquired 2,000 shares of Johnson & Johnson stock in a transaction that occurred on Friday, December 14th. The stock was acquired at an average price of $134.37 per share, with a total value of $268,740.00. Following the completion of the purchase, the director now directly owns 28,520 shares in the company, valued at approximately $3,832,232.40. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 514,187 shares of company stock valued at $74,951,528. 0.22% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY NOTICE: “Johnson & Johnson (JNJ) Earning Somewhat Critical Media Coverage, Analysis Shows” was reported by Daily Political and is owned by of Daily Political. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://www.dailypolitical.com/2018/12/18/johnson-johnson-jnj-earning-somewhat-critical-media-coverage-analysis-shows.html.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.
Recommended Story: Bear Market
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.